Rtw Investments 13F: Adds $19M to Repligen (RGEN) Stake

RTW Investments has increased its position in RGEN by 142,000 shares, as reflected in its latest Form 13F filing with the SEC. This move boosts its total holdings to 1,206,000 shares, representing a 13.3% increase. The value of RTW's stake in RGEN now stands at approximately $157.49 million.

What Changed in RTW Investments' RGEN Position

RTW Investments added 142,000 shares to its RGEN holdings, raising its total to 1,206,000 shares from 1,064,000 shares previously. This change represents a 13.3% increase in their stake, valued at $157.49 million as of the reporting period.

Other Institutional Activity in RGEN

In other institutional activity, BlackRock, Inc. reduced its holdings by 626,217 shares, ending with about 5,993,054 shares worth $706.1 million. Meanwhile, Price T Rowe Associates Inc /MD/ increased its stake by 279,080 shares, now holding 4,878,141 shares valued at $574.74 million. FMR LLC added 18,940 shares, bringing its total to 2,886,786 shares, worth $340.12 million. United Capital Financial Advisors, LLC made a modest increase of 3,118 shares, totaling 2,773,980 shares valued at $326.83 million. Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both reported large increases, with each adding over 2.3 million shares.

Repligen Corporation Stock Down 26.2%

RGEN shares are trading at approximately $130.59. The stock's 52-week range has seen a low of $0.0 and a high of $0.0, with moving averages not provided. The company's current financial ratios and metrics were not available in the latest report.

Insider Buying and Selling at Repligen Corporation

Several insiders, including Carrie Eglinton Manner and Nicolas Barthelemy, purchased 2,239 shares each on May 14, 2026. Martin Madaus and Glenn Muir also bought the same amount of shares on the same date. Additionally, Karen Dawes acquired 995 shares. These transactions were not part of a planned trading program.

Analysts Set New Price Targets

On June 3, 2026, HSBC maintained its 'buy' rating on RGEN with a price target of $150. Wolfe Research assumed coverage on June 2, 2026, with a 'buy' rating and a $145 target. RBC Capital reinstated its 'buy' rating with a $160 target on May 15, 2026. Other firms like JP Morgan and Barclays also maintained 'buy' ratings with targets of $165 and $160, respectively.

Bottom Line

RTW Investments' increased stake in RGEN reflects its confidence in the company's potential, as seen in its latest 13F filing. This backward-looking report shows RTW's position as of the filing date and may not represent its current holdings. Investors often track such filings to gauge institutional sentiment and market trends.